SCHEMBL13063205

SCHEMBL13063205

O=Nc1ccc(C(=O)N2CCN(c3nc(C(F)(F)F)nc(-c4ccncc4)c3-c3ccc(F)cc3)CC2)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.37
ALDH1A1 P00352 4/20 0.37
MAPK1 P28482 4/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TSHR P16473 3/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HSD17B10 Q99714 2/20 0.36
SMO Q99835 1/20 0.36
MAPK14 Q16539 4/20 0.35
MAPK11 Q15759 3/20 0.35
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
KCNH2 Q12809 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13063203 0.89 PDE4A (0.46) SMN1; SMN2ALDH1A1MAPK1MAPTKDM4E
SCHEMBL13062965 0.88 PDE4A (0.46) SMN1; SMN2ALDH1A1MAPK1MAPTKDM4E
SCHEMBL2082801 0.85 SLC2A1 (0.44) SMN1; SMN2ALDH1A1MAPK1MAPTKDM4E
SCHEMBL13062959 0.80 PDE4A (0.37) SMN1; SMN2ALDH1A1MAPK1KDM4EL3MBTL1
SCHEMBL2085020 0.75 CA12 (0.54) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2084783 0.75 CA12 (0.54) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2082946 0.72 SLC2A1 (0.46) SMN1; SMN2ALDH1A1MAPK1MAPTKDM4E
SCHEMBL12964298 0.71 HSD17B10 (0.52) SMN1; SMN2ALDH1A1MAPK1MAPTKDM4E
SCHEMBL14468819 0.69 PDE4A (0.61) SMN1; SMN2ALDH1A1MAPK1MAPTKDM4E
SCHEMBL2084529 0.69 SLC2A1 (0.48) ALDH1A1MAPTNPSR1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100329998-A1 NOVEL HETEROCYCLES ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100329998-A1 NOVEL HETEROCYCLES UACA, GPR4, CASP4 SMN1; SMN2 175/4885ALDH1A1 2623/4885MAPK1 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.